From @morgans analyst, Scott Power Just back from the World Diabetes Conference in Melbourne

Livewire Equities

Livewire

From @morgans analyst, Scott Power Just back from the World Diabetes Conference in Melbourne. Globally the prevalence of type 2 diabetes and obesity has reached epidemic proportions and the treatment of these diseases represents two of the largest and fastest growing healthcare challenges in the world. Yet despite the desperate need for effective clinical solutions, doctors have very few options that can safely and effectively treat both diseases simultaneously. One treatment in the early stage of adoption is GI Dynamics' EndoBarrier, which is the first endoscopically delivered device therapy for obese patients with type 2 diabetes. I heard from one of the surgeons experienced in treating patients as well as a patient who received the device 7 months ago. Although in early stages of adoption it is clear the momentum is building quickly both from the patient and doctors perspective. GID presented additional compelling clinical data further validating the device.


Livewire Equities
Livewire Equities
Livewire

The Livewire Equities feed brings you a range of insights that relate to Australian equities

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.